Caricamento...
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
BACKGROUND: Despite the availability of effective drug therapies that reduce low‐density lipoprotein (LDL)‐cholesterol (LDL‐C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity. Therefore, additional LDL‐C reduction may be warranted, especially for patients who are...
Salvato in:
| Pubblicato in: | Cochrane Database Syst Rev |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley & Sons, Ltd
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6478267/ https://ncbi.nlm.nih.gov/pubmed/28453187 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD011748.pub2 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|